ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1076

CKD Progression with Remote Pulmonary Artery Pressure (PAP) Monitoring in Heart Failure (HF)

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Gunasekaran, Deepthi, Yale University, New Haven, Connecticut, United States
  • Ullman, Lawrence S., Yale University, New Haven, Connecticut, United States
  • Aklilu, Abinet Mathias, Yale University, New Haven, Connecticut, United States
  • Turner, Jeffrey M., Yale University, New Haven, Connecticut, United States

CardioMEMS HF system is FDA approved for remote monitoring of PAP in patients with NYHA class III HF to reduce HF hospitalizations. Subgroup analysis of the CHAMPION trial with CKD patients reported a mean estimated glomerular filtration rate (eGFR) change of 1.0±14.48 ml/min/1.73m2 in 6 months in the CardioMEMs group and was similar in controls. Limited data is available on the role of remote PAP monitoring on kidney function in a real-world population that includes patients with advanced CKD over longer follow up.


This is a retrospective observational study where we included patients with CKD (eGFR <60 ml/min/m2 for atleast 90 days as screened by a nephrologist) and HF who were managed with the CardioMEMs HF system. Patients on dialysis, kidney and heart transplant recipients were excluded. Baseline characteristics were collected at the time of CardioMEMs implant. Outcome characteristics were collected after 2 years. Primary outcome was a composite of >40% decline in GFR, need for dialysis or transplant, and death.


Baseline characteristics are summarized in table 1. Of 42 patients, 73.8% had NYHA Class III HF, 71.4% were diabetic and 90.5% were hypertensive. 20 (47.6%) reached the primary composite outcome. 9 (21.4%) had >40% decline in eGFR, 4 (9.5%) required chronic dialysis and 10 (23.8%) died. While 18 (42.9%) patients developed progression of kidney disease, 17 (40.5%) patients had an improvement in their eGFR. Of those, 10 (23.8%) improved by more than 20%. The median change in eGFR at 2-yrs was +11.81% (16.88, 34.7). Median number of hospitalizations was 5.0 (3.0,7.0).


In this cohort of adults at high risk for renal progression at the time of cardioMEMs insertion, we observed an improvement in eGFR despite the expected renal progression. A larger study with a control group is warranted to better understand the impact of remote PAP monitoring on CKD progression.

Baseline CharacteristicsValues
Age, median (IQR)
Male, n (%)
Race/Ethnicity, n (%)
-African American
Diabetes, n (%)
Hypertension, n (%)
CKD Stage
-stage IIIA
-stage IIIB
-stage IV
-stage V
Etiology of CKD
-Presumed/proven DKD+/- CRS
-Hypertensive +/- CRS
-Not specified
LV EF, median (IQR)
<40%- n (%)
41-49%- n (%)
>50%- n (%)
Etiology of HF
-Not specified
Medications, n (%)
71 (63.25,77.00)
24 (57.1)

22 (52.4)
16 (38.1)
30 (71.4)
30 (71.4)

9 (21.4)
16 (38.1)
14 (33.3)
3 (7.1)

14 (33.3)
19 (45.2)
3 (7.1)
6 (14.3)
50.50 (35.00,60.00)
17 (40.47)
2 (4.76)
21 (50.00)

11 (26.2)
22 (52.4)
8 (19.0)
1 (2.4)

17 (40.5)
33 (78.6)
17 (40.5)
14 (33.3)
21 (50.0)